As expected, MMP9 mRNA expression levels allowed distinguishing NASH patients from control subjects, and HO patients and NAFL patients (p-value <0.05, ANOVA, Fig. 5B). This evidence concerns the gene MMP9 and metabolic dysfunction-associated steatohepatitis.